Chronic Hemodialysis
Chronic hemodialysis is a treatment for patients with severe kidney failure, where a machine filters waste and excess fluid from the blood, helping to maintain proper body function.
End-Stage Renal Disease: Rivaroxaban Dosing Study
We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Have you been on chronic haemodialysis for at least 3 months?
- Do you have severe liver problems (severe hepatic insufficiency)?
- Have you had surgery in the past 30 days?
- Have you had an ischaemic stroke (a type of stroke caused by a blockage) in the past 30 days?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Aban
Agublon
Assubex
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Regional Universitaire De Tours
Hemodialysis
La Riche, France
Sponsor: Centre Hospitalier Regional Universitaire De Tours
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.